Annular phased array transducer for preclinical testing of anti-cancer drug efficacy on small animals

Tamara Kujawska1, Wojciech Secomski1, Michał Byra1

  • 1Department of Ultrasound, Institute of Fundamental Technological Research, Polish Academy of Sciences, Pawińskiego 5b, 02-106 Warsaw, Poland.

Ultrasonics
|January 14, 2017
PubMed

Insights

This study developed a High Intensity Focused Ultrasound (HIFU) transducer for noninvasive tumor treatment in preclinical studies. The device accurately creates localized thermal lesions, enabling drug efficacy testing for solid tumors.

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Medical Imaging

Background:

  • Pulsed High Intensity Focused Ultrasound (HIFU) offers a noninvasive therapeutic approach for deep-seated solid tumors.
  • Preclinical studies require precise tools to evaluate anti-cancer drugs activated by HIFU beams.

Purpose of the Study:

  • Design and test a HIFU transducer for preclinical evaluation of HIFU-activated anti-cancer drugs.
  • Assess the transducer's capability to treat solid tumors in small animals at depths of 1-2cm.

Main Methods:

  • A spherical, 2-MHz, 29-mm diameter annular phased array transducer was designed and constructed.
  • Thermal lesions were induced in ex vivo pork loin using varying acoustic power and focal lengths.
  • Electronic control of time delays enabled beam focusing at specific tissue depths (10-20mm).
  • Lesion characteristics were analyzed using numerical simulations, ultrasound, MRI, and digital calipers.

Main Results:

  • The HIFU transducer successfully induced localized thermal necrotic lesions.
  • Magnetic resonance imaging (MRI) confirmed lesion locations and extents consistent with numerical predictions and caliper measurements.
  • Lesion edges were clearly defined on MRI, while ultrasound imaging showed fuzzier boundaries.

Conclusions:

  • The designed HIFU transducer is an effective noninvasive tool for inducing localized necrotic lesions.
  • It facilitates preclinical studies of HIFU-activated chemotherapeutics in small animal models.
  • The system allows precise lesion induction without damaging surrounding tissues.

Related Concept Videos